Biosimilars and Future Biotherapeutics

About Conference

We are pleased to welcome you to the 8th Annual Congress on Biosimilars and Future Biotherapeutics, taking place on March 15–16, 2027, in the vibrant and innovative city of San Francisco, USA. This premier international gathering will bring together leading scientists, researchers, regulatory authorities, biopharmaceutical experts, clinicians, healthcare professionals, industry leaders, and policymakers to explore the evolving landscape of biosimilars and the future of biotherapeutic innovation.

With a strong focus on advancing the development, accessibility, affordability, and adoption of biologic medicines, the congress will provide a dynamic platform for meaningful discussions on the latest scientific discoveries, regulatory developments, clinical advances, and market trends shaping the global biosimilars industry.

The congress will address a broad range of topics, including biosimilar development and regulatory approval pathways, analytical and clinical comparability, immunogenicity, pharmacovigilance, interchangeability, biobetters, real-world evidence, manufacturing technologies, market access, healthcare economics, and patient-centric approaches to biologic therapies.

Key Highlights of the Conference

• Renowned Keynote Speakers – Hear from leading scientists, regulatory experts, clinicians, industry executives, and thought leaders shaping the future of biosimilars and biotherapeutics.
• Cutting-edge Research Presentations – Discover the latest advances through keynote lectures, plenary sessions, oral presentations, and poster sessions covering emerging scientific and clinical developments.
• Interactive Workshops & Panel Discussions – Engage in expert-led workshops, case studies, and multidisciplinary panel discussions addressing regulatory, scientific, manufacturing, and commercial challenges.
• Networking Opportunities – Build connections with researchers, healthcare professionals, industry representatives, investors, policymakers, and potential collaborators from around the world.
• Industry & Innovation Showcase – Explore innovative technologies, manufacturing solutions, analytical platforms, digital tools, and emerging products presented by global biopharmaceutical companies, startups, and healthcare innovators.
• Regulatory & Market Access Insights – Gain valuable perspectives on evolving global regulatory frameworks, interchangeability, pricing, reimbursement, healthcare economics, and strategies for increasing biosimilar adoption.
• Future of Biotherapeutics – Explore next-generation biologics, novel therapeutic platforms, biobetters, advanced manufacturing approaches, and emerging technologies that are expected to transform the biopharmaceutical landscape.

Join us in San Francisco on March 15–16, 2027, for an inspiring exchange of scientific knowledge, innovative ideas, and global perspectives. Be part of the 8th Annual Congress on Biosimilars and Future Biotherapeutics and contribute to shaping the future of biologic medicines, biosimilar adoption, healthcare innovation, and equitable access to advanced therapies worldwide.

Sessions/Tracks

Next-Generation Biosimilar Development & Advanced Characterization

This session will explore the latest scientific and technological advances transforming biosimilar development, from molecular characterization to manufacturing and regulatory submission. Discussions will focus on advanced analytical platforms, high-resolution mass spectrometry, chromatography, capillary electrophoresis, structural and functional characterization, critical quality attributes (CQAs), and comparability assessment. Particular attention will be given to Quality by Design (QbD), Process Analytical Technology (PAT), continuous manufacturing, and data-driven approaches for improving process consistency and development efficiency. The session will also examine how bioinformatics, computational modeling, and artificial intelligence are being integrated into biosimilar development workflows.

Regulatory Science, Clinical Comparability & Global Biosimilar Harmonization

This session will address evolving regulatory expectations for biosimilars and the scientific principles used to demonstrate similarity, safety, and efficacy. Experts will discuss regulatory pathways across major markets, including the United States, European Union, Japan, and emerging biosimilar markets. The program will examine analytical similarity, PK/PD studies, immunogenicity assessment, clinical comparability, extrapolation of indications, switching studies, interchangeability, and the growing role of real-world evidence. Discussions will also explore international regulatory convergence and opportunities to reduce duplication in development programs while maintaining rigorous standards for patient safety.

Biosimilars in Clinical Practice: Oncology, Immunology & Rare Diseases

This session will focus on the expanding role of biosimilars across major therapeutic areas and their impact on patient care. Presentations will examine clinical experience with biosimilars in oncology, rheumatology, gastroenterology, dermatology, hematology, and rare diseases. Experts will discuss evidence supporting biosimilar use, treatment switching, immunogenicity, physician and patient confidence, and the integration of biosimilars into clinical guidelines. Special attention will be given to monoclonal antibodies, supportive-care biologics, and complex therapies used in cancer and immune-mediated diseases, as well as the opportunities and challenges of developing biosimilars for small patient populations.

 Future Biotherapeutics: Biobetters, Novel Biologics, Cell & Gene Therapies

This forward-looking session will explore the next generation of biotherapeutic innovation beyond conventional biosimilars. Topics will include biobetters, engineered monoclonal antibodies, bispecific antibodies, fusion proteins, long-acting biologics, novel protein formats, and advanced therapeutic platforms. The session will also examine the growing convergence between biologics and cell and gene therapies, including gene editing, viral and non-viral delivery systems, cell-based therapies, and personalized medicine. Speakers will highlight how these emerging technologies are addressing unmet clinical needs while creating new scientific, manufacturing, and regulatory challenges.

 Market Access, Health Economics & Global Adoption of Biosimilars

This session will examine the economic and healthcare-system impact of biosimilars and the factors influencing their successful adoption worldwide. Discussions will address pricing, reimbursement, procurement strategies, health technology assessment (HTA), cost-effectiveness, payer policies, physician incentives, substitution and interchangeability, and patient access. Experts will compare biosimilar adoption across established and emerging markets and explore how competition can generate healthcare savings while expanding access to biologic therapies. The session will also consider pharmacovigilance, post-marketing evidence, stakeholder education, and collaborative models needed to build confidence in biosimilars and support sustainable global adoption.

Market Analysis

The global biosimilars and future biotherapeutics market is expanding rapidly, driven by the growing demand for affordable biologic therapies, patent expirations of major biologics, and increasing healthcare expenditure. Biosimilars are gaining significant adoption in oncology, autoimmune diseases, diabetes, and chronic conditions, creating opportunities to reduce treatment costs and improve patient access.

Europe remains a leading biosimilar market due to established regulatory frameworks and strong adoption, while North America continues to grow with increasing approvals and market competition. Asia-Pacific is expected to be one of the fastest-growing regions, supported by expanding healthcare infrastructure and strong manufacturing capabilities in countries such as India and China.

Emerging trends include biobetters, bispecific antibodies, fusion proteins, advanced monoclonal antibodies, cell and gene therapies, AI-driven drug development, and innovative manufacturing technologies. Strategic partnerships, licensing, and collaborations are also accelerating industry growth.

Despite strong opportunities, challenges remain, including complex manufacturing, regulatory requirements, patent barriers, pricing pressures, and concerns regarding interchangeability and long-term safety. Overall, the market is transforming the global biologics landscape by improving affordability, expanding access, and driving innovation in next-generation biotherapeutics.